Xcout Intel
Braveheart Bio, Inc.
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Subscribe to see Braveheart Bio, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Braveheart Bio, Inc. at a glance
Braveheart Bio, Inc. is a biotechnology company headquartered in San Francisco, United States. It is publicly listed (BRVE) with a market capitalisation of $1.7B. Xcout tracks 35 named people at Braveheart Bio, Inc., including Travis Murdoch (CEO, President & Director). Xcout recorded 26 job postings from Braveheart Bio, Inc. in the last 90 days, naming tools such as NetSuite.
Braveheart Bio, Inc. leadership
- Travis MurdochCEO, President & Director
- Travis Murdoch, M.D.Chief Executive Officer and Board Director
- James Paul RickeyChief Financial Officer
- Paul RickeyChief Financial Officer
- Michele A. AndersonChief Development Officer
- Emil deGomaChief Medical Officer
29 more named people on record for Braveheart Bio, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Braveheart Bio, Inc.
Xcout recorded 26 job postings from Braveheart Bio, Inc. in the last 90 days, from a hiring record Xcout has kept since July 2026.
Tools named in Braveheart Bio, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see Braveheart Bio, Inc.'s hiring signals →
Recent Braveheart Bio, Inc. news
- IPOBraveheart Bio, Inc. Common Stock IPO on NASDAQ
- IPOIPO registration (S-1)
- IPOS.F. heart drug developer Braveheart Bio poised for 2nd- ...
- IPOIPO registration (S-1)
7 corporate events on record, with sources — see the full timeline →
Tech stack
Braveheart Bio, Inc. competitors
A few of Braveheart Bio, Inc.'s closest competitors — see the full list of competitors and alternatives →
Edgewise Therapeutics is a biopharmaceutical company that develops novel therapeutics for individuals facing serious cardiovascular diseases, such as hypertrophic cardiomyopathy and heart failure. The company focuses on muscle science and precision therapies to address unmet medical needs in patients and families.
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Bitterroot Bio is a privately held biotechnology company headquartered in Palo Alto, California, focused on the research and development of therapies for cardiovascular disease. The company operates as a biotechnology research firm and is engaged in clinical trials to evaluate its therapeutic pipeline.
Verve Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, dedicated to pioneering single-course gene editing medicines for cardiovascular disease.
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.
Get Braveheart Bio, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Braveheart Bio, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Braveheart Bio, Inc. in Xcout Intel
- 35 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 7 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access